União Europeia - português - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, aguda - agentes antineoplásicos - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

União Europeia - português - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

União Europeia - português - EMA (European Medicines Agency)

celgene europe bv - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

União Europeia - português - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidina betapharm é indicado para o tratamento de pacientes adultos que não são elegíveis para transplante de células-tronco hematopoiéticas (hsct) com:intermediário-2 e de alto risco, as síndromes mielodisplásicas (smd), de acordo com a internacional de prognóstico de scoring system (ipss),mielomonocítica crônica leucemia (cmml) com 10 % a 29 % de medula óssea blastos sem mieloproliferativas transtorno,leucemia mieloide aguda (lma) com 20% a 30 % de blastos e multi-linhagem de displasia, de acordo com a organização mundial de saúde (oms), a classificação de lma com > 30 % medula óssea blastos de acordo com a classificação da oms.

União Europeia - português - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidina acordo é indicado para o tratamento de pacientes adultos que não são elegíveis para transplante de células-tronco hematopoiéticas (hsct) com:- intermediário-2 e de alto risco, as síndromes mielodisplásicas (smd), de acordo com a internacional de prognóstico de scoring system (ipss),- mielomonocítica crônica leucemia (cmml) com 10-29 % de medula óssea blastos sem mieloproliferativas transtorno,- leucemia mieloide aguda (lma) com 20% a 30% de blastos e multi-linhagem de displasia, de acordo com a organização mundial de saúde (oms), a classificação de - aml com >30% medula óssea blastos de acordo com a classificação da oms.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - azacitidina - pó para suspensão injetável - 100 mg - azacitidina 100 mg - azacitidine - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

seacross pharma (europe) limited - azacitidina - pó para suspensão injetável - 100 mg - azacitidina 100 mg - azacitidine - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - azacitidina - pó para suspensão injetável - 100 mg - azacitidina 100 mg - azacitidine - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

zentiva portugal, lda. - azacitidina - pó para suspensão injetável - 100 mg - azacitidina 6.67 mg/ml - azacitidine - genérico - duração do tratamento: longa duração